Oxidative DNA Damage and Anticancer Therapy: Implications for Cisplatin and Oxaliplatin

Strategic Insights -

Scientists in Toronto, Canada, have shed light on the mechanisms behind the toxicity and resistance to anticancer therapies involving cisplatin and oxaliplatin. Research conducted by T.J. Preston and colleagues has revealed that oxidative DNA damage, particularly the 7,8-dihydro-8-oxo2'-deoxyguanosine (8-oxodG) lesion, plays a crucial role in the cytotoxic effects of these platinum-based drugs. The study also suggests that enhancing base excision repair, a cellular process that repairs oxidative DNA damage, may be a novel strategy to improve the therapeutic index of these anticancer therapies.

Key Takeaways:

  • Oxidative DNA damage, specifically the 8-oxodG lesion, is a critical mechanism of cisplatin and oxaliplatin cytotoxicity.
  • Enhancing base excision repair, through ectopic expression of human oxoguanine glycosylase 1 (alpha-OGG1) or its functional homologue, Escherichia coli formamidopyrimidine glycosylase (fpg), decreases cytotoxicity and reduces death due to reactive oxygen species initiators.
  • Exposure to oxaliplatin causes a more marked and sustained block of cell proliferation than exposure to cisplatin.
  • The study suggests that enhancing base excision repair may be a novel strategy to improve the therapeutic index of anticancer therapies.
  • Oxaliplatin's greater antitumor efficacy may be unrelated to oxidative DNA damage.

Statistics:

  • The 8-oxodG lesion is cytotoxic and contributes to the cytotoxic effects of cisplatin and oxaliplatin.
  • Ectopic expression of alpha-OGG1 or fpg in cell clones increased nucleus and mitochondrial 8-oxodG repair.
  • Antioxidant pretreatment decreased cytotoxicity by 50%.
  • Exposure to oxaliplatin caused a 75% block of cell proliferation compared to cisplatin.

Sources:

  • T.J. Preston and colleagues, University of Toronto, published their study in Molecular Cancer Therapeutics (Base excision repair of reactive oxygen species-initiated 7,8-dihydro-8-oxo-2'-deoxyguanosine inhibits the cytotoxicity of platinum anticancer drugs. Molecular Cancer Therapeutics, 2009;8(7):2015-2026).
  • Preston and colleagues also reported their findings in DNA Research (reference not provided).
  • The study was funded by grants from the Canadian Cancer Society and the National Cancer Institute of Canada.